Funding for Faculty

Siteman Funding Opportunities Newsletter

Download the Latest Siteman Funding Opportunities Newsletter (PDF)

The newsletter and the list of open opportunities on this page are not fully inclusive of all available cancer-related funding. Please be sure to consult other sources to learn of other opportunities not listed here.

August Deadlines

August 31 Application: Innovative Cancer Research Grants – Elsa U. Pardee Foundation

Additional Details

 RFP Snapshot: The Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers.

Max Amount and Period: No dollar limit, but must be supported by scope of project – 1  year

Eligibility: Post-docs who are on the tenure track and have a tenured mentor are eligible. Priority is given to researchers at non-profit institutions in the United States who are new to the field of cancer research, or to established research investigators examining new approaches to cancer cure.

Due Date: Application Due August 31, 2021

August 31 LOI: Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial NOT ALLOWED) – NIH/NCI

Additional Details

RFP Snapshot: The purpose of this opportunity is to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.

Max Amount and Period: $1.5 million over 3 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: Application Due August 31, 2021

September Deadlines

September 1 SOI: INTERNAL: Siteman Investment Program Research Development Awards (SIP-RDA)

Additional Details

RFP Snapshot: The SIP-RDA is designed to award development funding to faculty investigators to support pioneering cancer research and produce data to leverage further external peer-reviewed funding. SCC will fund the following mechanisms: New and Established Clinical Trials, Pre-R01, Pre-R01 with a Prevention & Control Emphasis, Pre-R01 for Collaborations with University of Missouri-Columbia, and Team Science.

Max Amount and Period: Varies from $200,000 to $800,000 over 2 years

Eligibility: The PI must have a full-time faculty appointment at Washington University (WU), Saint Louis University (SLU), or University of Missouri-Columbia (MU). Faculty from Saint Louis University and University of Missouri-Columbia are required to have a WU Siteman Cancer Center faculty member as co-PI. The contact PI submitting the application must be a Siteman Cancer Center member.

Due Date: Statement of Intent Due September 1, 2021

September 1: INTERNAL: SPORE in Leukemia Career Enhancement Program

Additional Details

RFP Snapshot: The goal of the Career Enhancement Awards is to recruit and support new independent investigators in the field of translational leukemia/MDS research.

Max Amount and Period: $75,000 for 1 year

Eligibility: The applicant must be a junior faculty member (Instructor or Assistant Professor) without R01 or equivalent grant support OR senior post-doctoral fellows who have a written commitment from their department chair indicating promotion to Instructor or Assistant Professor by the time of the award.

Due Date: September 1, 2021 at 5PM CST

September 1: Childhood Cancer Research Grant – Andrew McDonough B+ Foundation

Additional Details

RFP Snapshot: All research must be directly related to pediatric cancer and each applicant will be judged on the quality of science (including impact on field), innovation, quality of applicant, institutional environment, and budget appropriateness.

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicant must have a M.D., D.O., Ph.D., or PharmD. Degree. Must be an Assistant, Associate, or Professor, or an instructor with a minimum of a two-year commitment from an academic institution.

Due Date: September 1, 2021

September 6 LOI: Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed) – NIH/NCI

Additional Details

RFP Snapshot: This opportunity is to support the program “Cancer Target Discovery and Development” (CTD2, pronounced cee-tee-dee-squared). CTD2 will promote efforts to radically improve our understanding of the underlying etiology of cancer initiation, progression, and metastasis and to exploit this knowledge in clinically relevant context which includes intra-tumor heterogeneity, tumor microenvironment and other factors that result in “innate” or acquired treatment resistance.

Max Amount and Period: $3,750,000 over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: Letter of Intent Due September 6, 2021

September 7 LOI: Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24 Clinical Trial Not Allowed) – NIH/NCI

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to solicit Applications for the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center. The CAP-IT network will be formed by up to three U54 Specialized Centers.

Max Amount and Period: $1,200,000 over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: Letter of Intent Due September 7, 2021

September 7 LOI: Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed) – NIH/NCI

Additional Details

RFP Snapshot: The purpose of this opportunity is to solicit applications for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54). The overall goal of the CAP-IT Program is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

Max Amount and Period: $3,600,000 over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: Letter of Intent Due September 7, 2021

September 8 LOI: Conquer Cancer Now Award – Concern Foundation

Additional Details

RFP Snapshot: Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology. Concern Foundation for Cancer Research will not fund clinical trials, cancer epidemiology, or behavioral studies.

Max Amount and Period: $120,000 over 2 years

Eligibility: Eligible applicants are independent investigators at the level of Assistant Professor (or equivalent, with explanation). Successful proposals are usually from investigators who have been in their independent position and directing their own research program for more than one year, but have yet to obtain significant outside funding.

Due Date: Letter of Intent Due September 8, 2021

September 8: Clinical Investigator Career Development Award – Lymphoma Research Foundation

Additional Details

RFP Snapshot: The LRF Clinical Investigator Career Development Award (CDA) Program is designed to support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools. Eligible investigators must have no greater than five years of experience beyond completion of their fellowship or postdoctoral training (the five-year limit may be non-sequential in cases of pregnancy or illness).

Max Amount and Period: $225,000 over 3 years

Eligibility: Applicants for this award should be clinical physicians in one of the ACGME accredited specialties. The applicant must be an advanced fellow or junior faculty member with at least 2 years (24 months) of fellowship

or postdoctoral training and no greater than 5 years of experience beyond completion of his/her fellowship or postdoctoral training (the five year limit may be non-sequential) at the start of the award period (March 1, 2021). Applicant will dedicate 35 – 50% of their time in research.

Due Date: September 8, 2021

September 15: Paul Calabresi K12 Career Development Award – NIH/NCI

Additional Details

RFP Snapshot: The K12 Clinical Oncology program supports the development of postdoctoral scholars and junior faculty through patient oriented cancer research training, curricula, and mentored projects.

Max Amount and Period: $200,000 over 2 years (salary support); $50,000 over 2 years (research and travel)

Eligibility: The K12 Program expects applicants to be postdoctoral level trainees or early junior faculty level trainees who plan to conduct, or are conducting, clinical oncology research. They must be able to devote 75% professional effort to the program for a minimum of two years. Applicants cannot have been a PI on an NIH research grant (such as R01, R29, or P01) or a non-NIH equivalent to these grants.

Due Date: September 15, 2021 at 5PM CST

September 27: Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast Cancer – Pfizer Global Medical Grants

Additional Details

RFP Snapshot: “The intent of this RFP is to increase healthcare professionals’ knowledge and understanding of the clinical trial and real world evidence for the CDK 4/6i class. The two audiences of interest are as follows: 1) Medical oncologists and the cancer care team in community settings including rural and underserved locations and 2) institutional decision-makers such as managed-care professionals, pharmacy-managers, clinical pathway implementors, organized medicine leaders, etc.”

Max Amount and Period: $250,000 over 2 years

Eligibility: The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

Due Date: September 27, 2021 at 10:59PM CST

September 28: Pre-clinical and Translational Research in Multiple Myeloma – Pfizer Global Medical Grants

Additional Details

RFP Snapshot: This funding opportunity will only consider pre-clinical projects with a focus on multiple myeloma. See full RFP for more details on this specific areas of interest proposed.

Max Amount and Period: $150,000 over 2 years

Eligibility: The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy and affiliated with a host institution.

Due Date: September 28, 2021 at 10:59PM CST

October Deadlines

October 8: Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) – NCI/NIH/DHHS

Additional Details

RFP Snapshot: This funding opportunity “invites applications to support the validation of molecular/cellular/imaging markers (referred to as “markers” or “biomarkers”) and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI.”

Max Amount and Period: $1,025,000 over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: October 8, 2021

October 12 LOI: Research Centers for Cancer Systems Biology (U54 Clinical Trial Not Allowed) – NCI/NIH

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to solicit multi-project U54 Research Centers to address challenges in basic cancer biology that require a coordinated systems biology approach. These Research Centers will join the existing NCI-supported Cancer Systems Biology Consortium (CSBC). The goals of the CSBC are to (1) advance understanding of mechanisms that underlie fundamental processes in cancer; (2) support the broad application of systems biology approaches in cancer research; and (3) support the growth of a strong, stable, and diverse research community in cancer systems biology.

Max Amount and Period: $7,500,000 over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: Letter of Intent Due October 12, 2021 at 5PM CST

October 15 LOI: Division of Cancer Biology Multi-Consortia Coordinating Center (U24 Clinical Trial Not Allowed) – NCI/NIH

Additional Details

RFP Snapshot: “This FOA aims to create a common coordinating body to facilitate collaborations, resource sharing, and outreach activities across DCB programs. DCB research programs to be coordinated by the DCB Multi-Consortia Coordinating Center (MC2 Center) include the Cancer Cell Biology Imaging Resource (CCBIR), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Metastasis Research Network (MetNet), the Patient-Derived Models of Cancer Initiative (PDMC), and the Physical Sciences-Oncology Network (PS-ON). In carrying out its roles, the MC2 Center is expected to work collaboratively with DCB research program investigators, other investigators collaborating with DCB research programs, and NCI program staff.”

Max Amount and Period: $1,200,000 over 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: Letter of Intent Due October 15, 2021 at 5PM CST